Search clinical trials for: Unresectable Mesothelioma

Total 3014 results

AstraZeneca

Recruiting

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Unresectable Pleural Mesothelioma

Denmark, Italy, Australia, Korea, Republic of, Belgium, Poland, United States, Canada, Japan, United Kingdom, Spain, China, France, Taiwan, Norway, Brazil, Germany, Switzerland, South Africa, Turkey, Netherlands
Sun Yat-sen University

Recruiting

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Pleural Mesothelioma

China
Bristol-Myers Squibb

Recruiting

A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)

Mesothelioma, Malignant

Japan
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants (CheckMate 6DW)

Mesothelioma, Malignant

China
Nurix Therapeutics, Inc.

Recruiting

A Study of NX-1607 in Adults With Advanced Malignancies

Cervical Cancer | Gastric Cancer | Head and Neck Squamous Cell Carcinoma | Non-small Cell Lung Cancer (NSCLC) | Metastatic Urothelial Carcinoma | Ovarian Cancer, Epithelial | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Triple Negative Breast Cancer (TNBC) | Malignant Pleural Mesothelioma... and other conditions

United States, United Kingdom
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Triple-Negative Breast Carcinoma and other conditions

United States, Canada
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743)

Mesothelioma

Brazil, United States, China, Italy, Australia, Belgium, Chile, Colombia, France, Germany, Greece, Japan, Mexico, Netherlands, Poland, Romania, Russian Federation, South Africa, Switzerland, Turkey, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma | Unresectable Solid Neoplasm | Advanced Pleural Malignant Mesothelioma | Advanced Peritoneal Malignant Mesothelioma

United States
MedImmune LLC

Active, not recruiting

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma (Tremelimumab)

Unresectable Pleural or Peritoneal Malignant Mesothelioma

United States, Italy, Spain, United Kingdom, Belgium, Canada, Poland, France, Korea, Republic of, Hungary, Russian Federation, Germany, Australia, South Africa, Netherlands, Romania, Sweden, Israel, Denmark
Symphogen A/S

Active, not recruiting

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Solid Tumor | Metastatic Cancer

United States, Canada
European Organisation for Research and Treatment...

Active, not recruiting

Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma (NEMO)

Malignant Pleural Mesothelioma

United Kingdom, Belgium, Italy
Incyte Corporation

Active, not recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Cervical Cancer | Nasopharyngeal Carcinoma | Advanced Solid Tumors | Mesothelioma | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Anal Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1) | Urothelial... and other conditions

Finland, United States, United Kingdom, Belgium, Sweden, Denmark, Norway
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

Mesothelioma | Malignant Pleural Mesothelioma

United States
University Hospital Southampton NHS Foundation...
British Lung Foundation; University of Southampton

Active, not recruiting

Niraparib Efficacy in Patient With Unresectable Mesothelioma (NERO)

Mesothelioma, Malignant

United Kingdom
Memorial Sloan Kettering Cancer Center

Completed

A Study of Pembrolizumab and Cryoablation in People With Mesothelioma

Lung Cancer | Unresectable Mesothelioma

United States
PrECOG, LLC.
AstraZeneca; University of Sydney; Thoracic Oncology Group Australasia (TOGA)

Active, not recruiting

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R)

Mesothelioma | Malignant Pleural Mesothelioma | Pleural Mesothelioma

United States, Australia, New Zealand
Massachusetts General Hospital
Conquer Cancer Foundation

Active, not recruiting

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer (UPLIFT)

Stage IV Non-Small Cell Lung Cancer | Stage IV Bladder Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Immunotherapy | Immune Checkpoint Inhibitors | Stage IV Gastric Cancer | Stage IV Merkel Cell Carcinoma | Stage IV Colorectal Cancer | Stage IV Esophageal Cancer | Advanced Lung Cancer | Stage IV Renal... and other conditions

United States
Groupe Français de Pneumo-Cancérologie
Bristol-Myers Squibb

Active, not recruiting

Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE) (MESO-IMMUNE)

Malignant Pleural Mesothelioma | Unresectable Malignant Neoplasm

France
PrECOG, LLC.
AstraZeneca

Completed

Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505)

Mesothelioma | Pleural Mesothelioma

United States
National Cancer Institute (NCI)

Terminated

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Lung Cancer | Carcinoma, Esophageal | Malignant Pleural Mesotheliomas

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

Lung Cancer | Mesothelioma

United States
Shionogi

Completed

First-in-human Study of S-588210 (S-488210+S-488211)

Head and Neck Cancer | Esophageal Cancer | Lung Cancer | Mesothelioma | Bladder Cancer

United Kingdom
Health Pharma Professional Research

Withdrawn

A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma, Advanced | Malignant Pleural Mesothelioma, Unresectable

Mexico
Intergroupe Francophone de Cancerologie Thoracique

Completed

Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients (MAPS2)

Mesothelioma

France
Targovax Oy
Theradex

Unknown

A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma

To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy

Spain, France
Incyte Corporation

Withdrawn

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Advanced and/or Metastatic Solid Tumors | Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer | Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma
Morphotek

Terminated

Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM) (ARTEMIS)

Mesothelioma, Malignant

France, United Kingdom, United States, Germany, Australia, Italy
Swiss Group for Clinical Cancer Research

Completed

E-MOSAIC Electronic Tool to Monitor Symptoms

Cancer

Switzerland
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107

Malignant Mesothelioma
University of Chicago

Withdrawn

A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy

Malignant Pleural Mesothelioma (MPM)

United States
Memorial Sloan Kettering Cancer Center

Withdrawn

Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma

Malignant Mesothelioma

United States
National Cancer Institute (NCI)

Completed

Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura

Esophageal Cancer | Lung Cancer | Metastatic Cancer | Malignant Mesothelioma

United States
INSYS Therapeutics Inc
National Cancer Institute (NCI)

Completed

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Cancer

United States
Ottawa Regional Cancer Centre

Completed

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

Sarcoma | Head and Neck Cancer | Brain and Central Nervous System Tumors | Malignant Mesothelioma | Liver Cancer | Pheochromocytoma | Adrenocortical Carcinoma

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Interleukin-12 in Treating Patients With Cancer in the Abdomen

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Anal Cancer | Gallbladder Cancer

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer

Cancer

United States
Gruppo Italiano MEsotelioma

Unknown

A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma

Mesothelioma

Italy
Fudan University

Not yet recruiting

The Efficacy and Safety of Cadonilimab (AK104) as Induction and Consolidation Therapy for Locally Advanced/Unresectable NSCLC Patients Receiving Concurrent Chemoradiotherapy

NSCLC | Locally Advanced Lung Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

HER2-positive Breast Cancer

China
University Hospital, Rouen

Not yet recruiting

De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer (DIAMOND)

Metastatic Colon Cancer
KaliVir Immunotherapeutics

Not yet recruiting

A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001)

Kidney Cancer | Renal Cell Carcinoma | Cervical Cancer | Mesothelioma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Solid Tumor, Adult | Microsatellite Stable Colorectal Cancer | Melanoma Stage IV | Merkel Cell Carcinoma of Skin
Sun Yat-sen University

Not yet recruiting

FOLFOX Chemotherapy Plus Fruquintinib and Sintilimab After First-line Treatment in Unresectable Hepatocellular Carcinoma (FOLFOX)

Hepatocellular Carcinoma | Immunotherapy | Second-line Treatment | Anti-angiogenic Therapy | FOLFOX Systemic Chemotherapy
Institut für Klinische Krebsforschung IKF GmbH...
AstraZeneca; Universitätsklinikum Köln, Germany; Universitätsklinikum Düsseldorf...

Not yet recruiting

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Extrahepatic Cholangiocarcinoma | Unresectable Perihilar or Ductal CCA

Germany
National Cancer Institute (NCI)

Not yet recruiting

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Metastatic Urothelial Carcinoma | Unresectable Urothelial Carcinoma
Roswell Park Cancer Institute

Not yet recruiting

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Unresectable Triple-Negative Breast Carcinoma

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer (NEXUS-2)

Esophagus Cancer

China
AstraZeneca

Not yet recruiting

A PROSPECTIVE, MULTI-CENTER, PHASE 4 STUDY TO ASSESS THE SAFETY OF TRASTUZUMAB DERUXTECAN, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE IN INDIAN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED A PRIOR ANTI-HER2-BASED REGIMEN (STRIDE)

BREAST CANCER

Search clinical trials for: Unresectable Mesothelioma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations